Nodal mantle cell lymphoma (MCL) is a well-defined entity, but non-nodal leukemic cyclin D1 positive lymphoproliferative disorders have been reported and their relationship with MCL remains controversial and their prognosis heterogeneous. We prospectively studied the expression of cyclin D1 in CD5 positive leukemic B lymphoproliferative disorders at diagnosis and identified 65 cases overexpressing cyclin D1. We did not distinguish any clinical or biological criteria allowing one to identify a non-MCL group. Multivariate analysis identified age, anemia and p27kip1 expression as independent prognostic factors of survival. By univariate analysis, p27kip1 high expression proved to be the strongest predictor of prolonged survival. The median survival of p27 low expressors was 30 months, while it was not reached for p27 high expressors. A high level of p27 expression was often found associated with the absence of nodal involvement and the presence of somatic mutations, but neither of them was restricted to the p27 high expression group. In conclusion, we hypothesize that MCL and these cyclin D1 positive leukemic lymphoproliferative disorders represent a continuous spectrum of diseases. Determination of p27 expression level appears as a routine applicable test allowing identification of a subset of patients who could be considered for different therapeutic approaches.
Introduction
Nodal mantle cell lymphoma (MCL) is a morphologically welldefined lymphoma associated with overexpression of cyclin D1. 1 Upregulation of cyclin D1 by the heavy-chain enhancer element results from the t(11;14)(q13;q32) translocation, present in most if not all MCLs. 2 MCL is rare, accounting for approximately 5% of lymphomas, and has a remarkably poor prognosis with a median survival of 3 years. 3 Some patients present at diagnosis with additional leukemic features and usually experience an even more aggressive course. 4 Nonetheless, rare cases of non-nodal leukemic chronic lymphoproliferative disorders with t (11;14) have been reported and their relationship with MCL remains controversial. [5] [6] [7] Various denominations have been proposed including mantle cell leukemia, t(11;14) lymphocytosis or atypical CLL. [8] [9] [10] One of the issues is that these leukemic cases, nodal or not, appear to have a highly heterogeneous prognosis, some patients following an indolent course and not requiring treatment for years. 11, 12 Over the last decade, several attempts have been made to identify prognostic factors. Bone marrow involvement, blastic morphology, presence of enlarged lymph nodes, p53 mutations and INK4A/ARF deletions have been shown to influence outcome, [13] [14] [15] [16] [17] but none of these factors allows an identification of the good prognostic group. Several recent studies have focused on the mutational status of immunoglobulin V H gene since this appears to be a major prognostic factor in CLL. Whereas in most lymphomas mutational status appears related to the pre-or postgerminal origin of the cell, CLL shows a heterogeneous pattern of mutational status, and the absence of somatic mutations of the IgV H region identifies patients with a rapid disease progression. 18, 19 MCL cells were considered to be of pregerminal origin and early studies have reported the presence of unmutated VH genes in MCL. 20 Several studies have reported the presence of somatic mutations in a subset of MCL. 12, [21] [22] [23] [24] [25] Although none of the studies reports a statistically different survival advantage for mutated cases, a study by Orchard et al, 12 demonstrates that t (11;14) lymphocytosis is also heterogeneous with respect to IgV H mutations, with the presence of somatic mutations being restricted to the non-nodal group, and more frequently found among the long-term survivors.
Proliferation is a major prognostic issue in lymphomas. One of the major cell cycle regulatory proteins involved in cell proliferation and quiescence is p27kip1. 26, 27 The level of expression of p27 plays a critical role in the pathogenesis of many human tumors. 28, 29 In lymphomas as in solid tumors, low levels of p27 define a group of patients with poor outcome. [30] [31] [32] [33] MCL cells have been shown to express a very low amount of p27 protein, 34, 35 notably when compared with the other CD5 þ lymphoproliferative disorder, CLL. 36 Over a period of 7 years, in the three participating centers we have prospectively assessed the expression of cyclin D1 in all patients presenting with CD5 þ monoclonal lymphocytosis, whether histology was available or not. We identified 65 patients and studied the clinical presentation, the morphological features, the immunophenotype, the cytogenetics and the level of expression of cyclin D1 and p27. The level of p27 expression proved to be the strongest predictor of survival by both univariate and multivariate analysis regardless of the presence of lymph nodes.
Material and methods
with co-expression of CD5 and CD19 documented by flow cytometry. Among the several hundreds of patients tested, we identified 65 cases of cyclin D1 positive leukemic lymphoproliferative disorder (LPD) through systematic determination of cyclin D1 expression by competitive RT-PCR in leukemic B lymphoproliferative disorders at diagnosis. The median followup of the cohort was 47 months.
Clinical charts of patients were reviewed and the following data were collected and analyzed: age, gender, WHO performance status, presence of superficial lymphadenopathy, spleen and/or liver enlargement, and presence of extra nodal disease. Subsequent laboratory findings were also collected: WBC and lymphocyte counts, hemoglobin level, platelet count, LDH and b 2 microglobulin serum levels.
Cell morphology was analyzed independently by two cytologists on May-Grü nwald-Giemsa stained peripheral blood smears. Patients were categorized into groups according to the FAB recommendations. The following criteria were reviewed: cell size, nuclear/cytoplasmic ratio, density of chromatin, presence of nucleoli, nuclear shape, cytoplasmic features and percentage of prolymphocytes.
Biopsy specimen were fixed and paraffin-embedded for histopathologic diagnosis. In each center, lymph node and bone marrow histology were reviewed by a hematopathologist and cases were classified according to the WHO classification of lymphoid neoplasms. 37 
Immunophenotypic analysis of circulating B-cells
Flow cytometric analysis was performed on Becton Dickinson (BD) FACS Calibur or Coulter Epics XL-MCL using a lymphocyte gate. Results were analyzed using CellQuest s software system (BD) or System II s (Coulter). Immunophenotyping was performed on whole-blood samples or peripheral blood mononuclear cells (PBMC) isolated by density gradient centrifugation. Multiparametric analysis used the following directly conjugated antibodies: anti-CD19, CD20, CD22, CD23, CD79b, IgL kappa, IgL lambda, FMC7, CD10, CD103, CD5, CD3. Isotype control antibodies were used in all assays to determine positive and negative results. We used the RMH guidelines proposed by Matutes et al 38 for scoring lymphoid disorders, positivity threshold was set at 30% of the B-cell population.
Cytogenetical analysis
Peripheral blood cells were incubated 72 h with TPA. The chromosomes were studied by Heat using Giemsa banding technique (RHG). Dual color fluorescence in situ hybridization (FISH) techniques were performed on metaphase and interphase nuclei with 11q23 CCND1 probe (Vysis) and 14q32 IgH probes (IgH Vysis or 158A2BAC).
Cytogenetical and FISH results were described according to ISCN 91 and 95. 39 
Molecular and cell cycle analysis
Expression of cyclin D1 was determined using competitive RT-PCR on mononuclear blood cells as described by Uchimaru et al. 40 Protein expression of p27 /kip1 was studied by Western blot as described previously. 36 Briefly, whole-cell protein extracts were prepared by lysing 1-2 
Mutational status
RNA was isolated from cryopreserved cells using Trizol reagent and converted to cDNA using the first strand cDNA synthesis kit (Pharmacia). PCR reactions were performed using a series of seven specific leader region consensus primers for the human Ig V H gene families in conjunction with specific anti sense Cm primer. PCR products were analyzed on 1.5% agarose gels and visualized with ethidium bromide staining. PCR products were then purified with a Wizard PCR and Preps kit (Promega) and directly sequenced. Nucleotide sequences were compared to those in the V H base sequencing directory and the percentage homology to germline configuration was defined.
Statistical methods
Overall survival was calculated from the date of diagnosis until the patient's death or last visit. Actuarial survival probability curves were analyzed and plotted according to the method of Kaplan and Meier and compared using the log-rank test. Differences in the distribution of variables between groups were determined using Pearson's w 2 test or Fisher's exact test for categorical data, and the nonparametric Mann-Whitney test for continuous data.
Results

Clinical data
Clinical and biological features are summarized in Table 1 . Clinical features were available for 60 patients. The mean age at diagnosis was 66 years with a male predominance (75%). B symptoms including fever, night sweat and weight loss were reported in 18/60 patients (30%). The most frequent clinical finding was the presence of a splenomegaly in 45/60 cases (75%). In all, 53% patients (32/60) presented with peripheral lymphadenopathy. As it has been suggested previously that absence of peripheral adenopathy might identify a subset of patients with more stable disease, 41 we considered all clinical and biological features with respect to the presence (nodal group) or absence (non-nodal group) of lymph nodes (Table 1) . Among the 32 patients of the nodal group, the majority 28 had associated splenomegaly and isolated lymph node involvement was observed in four cases only. Liver involvement was rare and always associated with splenomegaly. Among the 28 patients of p27KIP1 in lymphoproliferative disorders R Letestu et al the non-nodal group (47%), 18 cases had isolated splenomegaly and a strictly leukemic form was observed in 10 patients. Altogether, these LPD experienced a rapidly progressive disease with a median survival of 36 months, similarly to what has been observed in MCL. 13, 42 However, we observed that a subset of patients followed an indolent course, some of them remaining untreated for several years. Data concerning treatment were available for 53 patients with a follow-up of 4 years: 44 of them received very similar chemotherapeutic regimens mostly based on CHOP chemotherapy with or without intensification by autologous stem cell transplantation whereas nine patients remained untreated. Therefore, there was no impact of the type of treatment on outcome, and the mortality rate was related in most cases to initial or secondary refractoriness and fatal evolutive disease.
Among clinical parameters, the presence of B symptoms or liver involvement was significantly associated with a shorter outcome using univariate analysis (P ¼ 0.003 and 0.049, respectively) but not the presence of nodal disease. When comparing nodal vs non-nodal groups, the overall survival was not significantly different.
Laboratory data
At diagnosis, the presence of a blood lymphocyte count 44 G/L was one of our inclusion criteria; therefore, median lymphocytosis was 19 Univariate analysis identified anemia below 12 g/dl as the only biological parameter significantly associated with a poor prognosis (P ¼ 0.026). There was no significant difference between nodal and non-nodal presentation for these data.
Morphological analysis
Cytological findings on blood smears were reviewed for all patients. In 46 (70%) cases, the presentation at diagnosis with a polymorphic lymphoid population was suggestive of leukemic MCL, among which four cases could be considered as blastoid variants, because of the presence of a subset of nucleolated large cells. A minority of patients, six out of 65 (9%), presented with morphological features of monomorphic mature lymphocytes analogous to CLL. Of note, these patients were distributed in both nodal and non-nodal groups, and none of these had CLL phenotypic features (RMH score o3). Interestingly, in nine cases (15.2%), blood smear examination found the presence of a small subset of villous cells with irregular cytoplasmic contours resulting in small expansions. The morphology had no identifiable prognostic impact, either considering each presentation (CLL-like, presence of villous cells and presence of prolymphocytes) separately or as a single non-typical category. Lymph node biopsy was performed in 14 cases out of the 31 patients presenting with peripheral adenopathy (45%). In all cases, a diagnosis of MCL was established. Similarly, bone marrow biopsy was performed in 23 additional cases and bone marrow involvement was present in 100% of cases. Although always difficult to assert on bone marrow morphology, the diagnostic of MCL was not controverted in any case.
Immunophenotype
In all 65 patients, the circulating lymphocytes co-expressed CD19 and CD5. However, no typical phenotype of CLL was observed. In contrast to the low levels of expression of CD20 observed in CLL, CD20 was highly expressed in all but one case, and FMC7 was expressed in 57/65 cases (87.7%). The intensity of CD22 and surface immunoglobulin light chains were medium to high in 40/65 (61.5%) and 57/65 (87.7%) of the cases, respectively. Although each case was light chain restricted, there was no clear imbalance of light-chain expression noted, the kappa to lambda ratio being 1.24. CD23 was negative in only 39/65 (60%). In the 40% cases expressing CD23, its expression was always dim and consistently lower than what is commonly observed in typical CLL. Unvariate analysis for survival failed to identify any prognostic marker among immunophenotypic findings. When comparing further the characteristics of nodal and non-nodal groups, only the intensity of CD23 labeling appeared not to be evenly distributed in both groups, CD23 being more often negative in the nodal group (24/ 32, 75%) than in the non-nodal group (11/28, 40%) (P ¼ 0.017).
CD10 was negative in all tested cases and CD103 was negative in all patients tested. Unexpectedly, DBA44 positivity was present in 14/24 cases tested (58.3%), but was not concordant with the presence of circulating villous lymphocytes.
Cytogenetics and molecular genetics
Cytogenetical findings were available for 52 patients. Cytogenetical study was not performed in eight cases, and five patients were considered as unevaluable because of the absence of FISH analysis despite the absence of mitosis (three cases) or undetectable t(11;14) (two cases). Among the 52 evaluable cases, a t(11;14)(q13;q32) translocation was detected in 90% of cases by conventional karyotype and/or FISH. A complex karyotype was observed in 16 patients (30.8% of cases). In five of them, no t(11;14)(q13;q32) could be demonstrated; however FISH was positive in all the three patients tested. Complex karyotype was observed within nodal and non-nodal groups with the same occurrence (32 and 33% respectively).
Normal karyotype by conventional cytogenetic analysis was reported in nine cases (16%) and all of these cases were found to be positive for t(11;14) using FISH analysis. In seven cases no mitosis could be obtained; among these only two could be tested by FISH and presented IgH-bcl1 rearrangement.
In conclusion, we demonstrated in at least 90% of the patients that cyclin D1 overexpression resulted from IgH-bcl1 rearrangement due to t(11;14)(q13;q32) translocation. We did not identify any case in which t(11;14)(q13;q32) was absent by FISH analysis.
Cyclin D1 expression
Cyclin D1 overexpression being an inclusion criterion, it was present in all 65 patients of the study. Cyclin D1 overexpression was evidenced at RNA level by competitive RT-PCR. As competitive PCR is not relevant for a quantitative evaluation of cyclin D1 expression, we determined cyclin D1 protein expression by Western blotting with a selective anti-cyclin D1 antibody. Protein expression was present in all cases, and the level of expression varied among cases. No correlation between the level of expression of cyclin D1 and clinical or biological findings or survival was evidenced.
IgV H gene mutational status
IgV H gene analysis was performed for 24 patients: 12 nodal and 12 non-nodal cases. As shown in Figure 3 , the presence of somatic mutations had little predictive value on p27 status or survival. In the non-nodal group, only one case had unmutated IgV H genes, three had 97% homology and eight harbored 4-9% somatic mutations. Nonetheless, even in the nodal form, presence of somatic mutations was noted: 2/12 cases were heavily mutated, and 4/12 cases showed 97% homology with the consensus sequence. There was a skewed IgV H usage as recently reported 23 with five individual V H genes, V4-34, V3-23, V4-59, V1-08, V3-21, found associated with half of the cases in a large series of nodal MCL, which accounted for 11/24 (46%) of our cases with a similar association with the mutational status. The presence or absence of somatic mutations did not have significant impact on survival but the number of patients is too small to draw definite conclusions from that observation.
p27 KIP1 expression
Expression of p27 was evaluated by Western blotting and quantification was assessed as previously described. 36 We distinguished two groups based on p27 level of expression: one, referred to as p27À group, with a p27 expression between 0 and 0.1 units, consistent with what we observed previously in histologically proven leukemic MCL 5 and lower than ever detected in CLL, and one denoted as p27 þ , with a median p27 level of 0.3, within the range of what is observed in CLL. 36 Patients appeared unevenly distributed in these two groups (Figure 1) . The p27À group, with a median 0.01 (0-0.09), gathered 47 patients (72%) while the p27 þ group with a p27 median expression of 0.31 units (0.1-1.27) included only 18 patients (28%). The p27 expression appeared to have a strong impact on survival as evidenced by univariate analysis. The median survival of p27À patients was 30 months, while it was not reached for p27 þ patients (P ¼ 0.006, logrank test) (Figure 2 ).
Multivariate analysis for survival
When a multivariate analysis was performed on the 60 patients for which complete data were available, including clinical and biological data previously described, only age, anemia and p27 KIP1 expression level were significantly associated with survival (Cox). Neither the presence of lymphadenopathy nor other biological tested parameters had an impact on survival.
Differential characteristics according to p27 level
We aimed at identifying the characteristics of the two p27 subgroups as summarized in Table 2 . The presence of nodal involvement was the only significantly different clinical parameter between the two groups (P ¼ 0.007). Altogether, p27 þ patients presented more often with a non-nodal form. However, nodal presentation did not exclude high p27 expression since 4/18 of p27 þ patients had lymph node enlargement. A lymph node biopsy was performed in three of these four cases and the diagnostic of MCL was carried out for all of them, and only one harbored a blastoid variant. Another feature of the p27 þ group lies in treatment requirement, and the majority of untreated patients were found among p27 high expressors. Among those, 7/14 patients are alive without treatment with a median followup of 4 years. Conversely, among the low expressors, only 2/39 remain untreated with a median follow-up of 3 years. Only 6/39 treated patients are doing well, all after intensive chemotherapy.
A high level of p27 expression was often found associated with the presence of somatic mutations. However, neither the presence of somatic mutations was restricted to the p27 þ group, nor unmutated IgV H was found only in p27À cases. Figure 3 shows that the presence of somatic mutations and the level of p27 expression are related but not redundant, and brings a visual representation that outcome is clearly more linked to p27 level than mutational status.
No morphological presentation could be significantly associated with p27 status. Notably, the six patients with CLL-like morphology belonged to the p27À group. Neither CD23 positivity nor any other immunophenotypic marker expression was significantly different between the p27 þ and p27À groups. Other parameters such as lymphocyte count, anemia, thrombocytopenia or cyclin D1 expression level were not related to p27 expression. Although numbers are too low to allow statistical analysis, p27 remains discriminant within both groups when considering nodal and non-nodal cases separately (Figure 2b ).
Discussion
During a period of several years, we studied prospectively all newly diagnosed CD5 þ leukemic lymphoproliferative disorders regardless of the clinical presentation and of whether or not a diagnostic was determined by other means. By this strategy, we identified 65 patients in whom cells overexpressed cyclin D1 at diagnosis. Limiting the study to CD5 þ cases allowed one to exclude all potential confusion with hairy cell leukemia, and limiting potential discussion of marginal zone lymphomas to very rare CD5 þ cases whose existence remains controversial. 43, 44 No patient was diagnosed as typical CLL when the criteria of having both typical morphology and an RMH score above 3 were applied. RMH score was 2 in 27 patients and below in 18 patients. There was no case in which cyclin D1 could be demonstrated to result from a mechanism other than t (11;14) translocation. In all patients for which histology was available, it was typical or compatible with MCL. Therefore, all cases fulfilled the diagnostic criteria as described by the WHO classification. 37 Our observations are in agreement with a recent report by Orchard et al. 12 showing that no criteria among this cohort of patients allowed us to identify a non-MCL group.
Nonetheless, the course of the disease appears dramatically different among these patients, and further subclassification of these cases is warranted. We first examined the incidence of the presence or absence of lymphadenopathy. When comparing nodal and non-nodal cases, there were little differences among the clinical and biological parameters. The only statistically significant difference was the expression of CD23. CD23 dim positivity has already been reported in MCL. 45, 46 Even if its expression appeared more frequent in the non-nodal group, it was always dim and significantly lower than that observed in CLL. Although median survival appeared longer in the nonnodal group (41 months) than in the nodal group (29 months), the overall survival was not significantly different by univariate analysis, nor was it selected by multivariate analysis. In order to have further insight into these non-nodal cases, we investigated the mutational status of IgV H genes of 12 cases of each group. Although previous publications have suggested that MCL derived from a naive B-cell and had germline V H genes, several groups recently found that a subset of approximately 20-30% MCL harbored somatic mutations.
12,21-23 Orchard et al 12 identified a strong correlation between absence of lymphadenopathy and presence of mutated V H genes in their leukemic cases. 12 Our results are concordant in finding 3% or more mutations in most of the non-nodal cases (8/12) . Although the number of patients is small, we also did not find any prognostic impact of mutational status.
It is also noteworthy that among our series 7/24 cases had a 97% germline homology. This finding is in agreement with the study of Kienle et al 23 and raises the question of the adequate threshold for considering the presence of somatic mutations as significant. Similar concern has been brought about in CLL and a clear consensus has not been reached yet, but the number of CLL cases with a 97% germline sequence homology represents less than 5% cases. 47 Moreover, the prognostic significance of mutational status in CLL is not questionable. Further studies are therefore warranted to elucidate the physiopathological meaning of mutational status and its prognostic impact in MCL. p27 expression in p27 positive and p27 negative groups as compared with CLL patients. Protein expression of p27 /kip1 was studied by Western blot (a), whole-cell protein extracts were submitted to SDS-PAGE. After transfer onto a polyvinylidene difluoride membrane, protein binding sites were blocked in 5% nonfat dry milk PBS, membrane was washed and incubated with HRP-linked secondary antibody. Signals were detected by enhanced chemoluminescence and quantitated by densitometry. The p27 value was expressed as the ratio of the signal obtained to that of the same positive control. We distinguished two groups based on p27 level of expression (b). P27 negative group was defined by an expression between 0 and 0.1, this group gathered patients (72%) with a p27 median expression of 0.01 units (0-0.09) lower than ever detected in CLL. P27 positive group (18 patients, 28%) showed a median p27 level of 0.31 units (0.1-0.27), p27 expression in the positive group is within the range of what is observed in 35 typical CLL samples.
Finally, we found the same biased usage of V H genes as described in recent reports on MCL. [21] [22] [23] For example, Kienle et al 23 found five individual V H genes associated with 50% of cases in a large series of nodal MCL, which accounted for 11/24 (46%) of our cases with a similar association with the mutational status. This V H use contrasts with what is commonly observed in CLL 48 and brings another argument to consider these cases as undistinguishable from nonleukemic nodal MCL. Overall survival of p27 þ and p27À patients in the complete series and in nodal and non-nodal groups. Actuarial survival probability curves were analyzed and plotted according to the method of Kaplan and Meier and compared using the log-rank test. The p27 expression appeared to have a strong impact on survival as evidenced by univariate analysis. The median survival of p27À patients was 30 months, while it was not reached for p27 þ patients (P ¼ 0.006, logrank test). Recently, gene expression profiling has identified proliferation signature genes as a strong predictor of the length of survival in nodal MCL: 58% of the survival prediction genes belonged to the proliferation gene expression signature, and these genes identified patients with significantly different survival times. 49 However, even if cyclin D1 expression participated in the proliferation signature, it did not account for a major part, reflecting the fact that additional oncogenic events are present.
The p27 protein is a physiological negative regulator mainly involved in cell cycle arrest. 50 Its level of expression is inversely correlated to proliferation index in many tumors and lymphomas, and low levels of p27 are associated with aggressive tumors with a high proliferation rate and a poor prognosis. 30, 31, 33 In MCL, whether assessed on whole cellular extracts or by immunohistochemical staining, the levels of p27 are drastically reduced. 34, 35 Conversely, in CLL, we have shown previously that p27 expression was high and related to defective apoptosis. 36, 51 In the present study, we demonstrated that p27 expression was the stronger survival predictor of all tested parameters. Distribution of p27 level of expression easily identified two distinct subgroups. All cases considered as low expressors had a barely detectable p27 expression, within a very narrow range, lower than what is observed in normal lymphocytes and CLL and this group represented two-thirds of the patients. Among the low expressors, p27 did not allow discrimination of patients with an even more unfavorable outcome. Conversely, in the group of high expressors, including only 18/65 patients, the median the p27 level was 30 times higher than in the low expressors, and was within the range observed in other chronic lymphoproliferative disorders. These patients had a remarkably indolent course. Expression of p27 was significantly higher in the non-nodal group, but the presence of lymph nodes was observed in four patients with high p27 expression. Conversely, 15 patients had a low p27 expression and no lymphadenopathy. When considering separately nodal and non-nodal groups, the expression of p27 remained of significant prognostic value within both groups. Similarly, even if a high level of p27 was often associated with the presence of IgV H somatic mutations, we found elevated p27 in some unmutated cases as well. Nonetheless, expression of p27 was far more distinctive between good and poor prognosis than the other parameters.
Whatever the cell type, regulation of p27 occurs predominantly at the post-transcriptional level, which is consistent with the fact that p27 RNA expression does not belong to the proliferation signature identified by microarray analysis in MCL. In general, two main pathways contribute to release the cell from p27 inhibition. The p27 protein is sequestered by the cyclin D-cdk4 complexes, without inhibiting their kinase activity, and furthermore increasing the stability of these complexes. 52, 53 Conversely the presence of p27 in cyclin Ecdk2 complexes inhibits their kinase activity and the titration of p27 by cyclin D-cdk4 complexes releases cyclin E-cdk2 complexes. 54, 55 The activity of cyclin-cdk complexes allows phosphorylation of the pocket proteins such as pRb and subsequent progression through G1. 56 Active cyclin E-cdk2 complexes are able to phosphorylate p27, leading to its degradation through the ubiquitin-proteasome pathway, allowing subsequent progression into the cycle. 57, 58 Previous studies have pointed out the role of a large amount of cyclin D1 protein into the reduced expression of p27 in MCL. 59 We did not find a lower expression of cyclin D1 protein in the indolent cases with a high p27 expression (data not shown). Therefore, higher expression of p27 is likely to be the critical step disrupting the stochiometric equilibrium between cyclin D1 and p27. A high expression of p27 might escape the buffering capacity of cyclin D1-cdk4 complexes and remain efficient in repressing cyclin E-cdk2 complexes, leading to reduced proliferation, consistent with the good prognosis of cases with minimal proliferation markers evidenced by microarray analysis in MCL. 49 Mechanisms leading to this elevated p27 protein expression remain unclear. In normal cells, degradation of p27 through the ubiquitin-proteasome pathway is targeted by interaction with Skp2, a member of the F box family, belonging to the SCF ubiquitin ligase complex. 60 In reactive lymphoid tissues and high-grade lymphomas, Skp2 expression is inversely correlated to p27 expression. 61 In MCL, although an increased degradation of p27 through the ubiquitin-proteasome pathway has been suggested by the use of proteasome inhibitors, 62 previous studies have failed to demonstrate an increased expression of Skp2 in aggressive cases. 63 We did not find a differential expression of Skp2 in our cases as well (data not shown). Therefore, the mechanisms leading to the elevated p27 expression in indolent cases remains unexplained at the present time and further experimental studies are warranted.
In conclusion, cyclin D1 positive leukemic lymphoproliferative disorders cannot be individualized from nodal MCL by any means, even if most indolent cases appear to fall into a nonnodal Ig mutated category. We believe that MCL and these cyclin D1 positive leukemic lymphoproliferative disorders represent a continuous spectrum of diseases in which the proliferative potential -as identified by genomic signature or p27 expression -plays a major role. Mechanisms leading to this p27 elevated expression are under study. Nonetheless, determination of p27 expression level appears as a routine applicable test of significant prognostic impact. Identification of a subset of patients with a favorable indolent course should allow one to consider them for different therapeutic approaches. Distribution of somatic mutations according to p27 KIPI and survival status. Schematic representation of the percentage of V H homology in two groups of 12 patients selected for their low or high expression of p27 KIPI. A high level of p27 expression was often found associated with the presence of somatic mutations. Alive (J) and dead (K) patients are unevenly distributed in the two groups.
